Grove Biopharma's last reported valuation, Apr 2025. Nothing priced has surfaced since.
- ·The complete investor list: 13 names
- ·Watch Grove Biopharma: the Monday email on marks, rounds and moves
Valuation timeline
0 priced rounds · 32 daily marks since · Sep 2026 – Oct 2026Membership and data by Private Market View
Grove Biopharma funding history
No funding rounds for Grove Biopharma are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Grove Biopharma valuation
Grove Biopharma's last reported valuation was $64 million in Apr 2025. No priced round, secondary trade or fund mark has surfaced since.
How Grove Biopharma's valuation is determined
Private company valuations aren’t quoted on an exchange — they’re established in moments: a priced funding round sets a post-money valuation, secondary trades print at a price per share, and SEC-registered funds holding the stock report fair-value marks in their N-PORT filings.
For Grove Biopharma, the most current credible signal sets the number and the older ones confirm it: a live secondary-market price first, then three or more recent prints, then institutional fund marks, and otherwise the last priced round, which never decays. The valuation is the last round’s post-money moved by the price change since that round, so no share count is assumed. Today it is set by last reported valuation. Question about this number? Full methodology →
Frequently asked about Grove Biopharma
- What is Grove Biopharma worth?
- Grove Biopharma is valued at $64.0M as of Oct 2026. Grove Biopharma's last reported valuation, Apr 2025. Nothing priced has surfaced since.
- How much has Grove Biopharma raised?
- Grove Biopharma has raised $44.0M in total funding across its recorded rounds.